This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Zenocutuzumab
DrugBank Accession Number
DB15559
Background

Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).

Type
Biotech
Groups
Investigational
Synonyms
  • Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer
  • Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
  • Zenocutuzumab
External IDs
  • MCLA-128

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Zenocutuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Zenocutuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Zenocutuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Zenocutuzumab.
AmivantamabThe risk or severity of adverse effects can be increased when Zenocutuzumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Zenocutuzumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Zenocutuzumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Zenocutuzumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Zenocutuzumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
AE72RB1W1X
CAS number
1969309-56-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentMetastatic Breast Cancer1
2RecruitingTreatmentNRG1 Fusion / NSCLC Harboring NRG1 Fusion / Pancreatic Cancer Harboring NRG1 Fusion / Solid Tumours Harboring NRG1 Fusion1
Not AvailableAvailableNot AvailableBreast Cancer / Cholangiocarcinoma / Colorectal Cancer / Head and Neck Carcinoma / Malignant Neoplasm of Pancreas / Non-Small Cell Lung Carcinoma (NSCLC) / NRG1 / NRG1 Fusion / Prostate Cancer / Renal Cell Carcinoma / Solid Tumor, Unspecified, Adult / Unknown Primary Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 17, 2019 15:15 / Updated at February 21, 2021 18:55